Viking Therapeutics, Inc.
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults who are obese or overweight with one or more weight related comorbid conditions without Type 2 Diabetes Mellitus.
Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent. 2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated). * Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. * Cardiovascular disease includes, for example, ischemic cardiovascular disease, NYHA Functional Class I-III heart failure. * BMI calculated at the screening visit will be used to determine eligibility. Exclusion Criteria: 1. History of or current…
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily
Placebo comparator administered orally once daily